EGFR and colorectal carcinoma: Activated K-ras was shown to be associated with decreased responsiveness to targeted therapies such as anti-epidermal growth factor receptor (EGFR) antibodies in metastatic CRC as well as increased aggressiveness of CRC [9-12].